<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427127</url>
  </required_header>
  <id_info>
    <org_study_id>RAMS</org_study_id>
    <nct_id>NCT01427127</nct_id>
  </id_info>
  <brief_title>Effect of Ramosetron on Bowel Motility After Colorectal Resection</brief_title>
  <official_title>Effect of Ramosetron on Bowel Motility and PONV After Laparoscopic Stomach and Colorectal Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ramosetron is effective in preventing postoperative nausea and vomiting. Several studies&#xD;
      reported that ramosetron is also effective treatment diarrhea-predominant irritable bowel&#xD;
      syndrome. The investigators examine the effect of ramosetron used for preventing&#xD;
      postoperative nausea and vomiting on bowel motility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ramosetron, a new potent and long-acting selective 5-HT3 receptor antagonist, is effective&#xD;
      for preventing postoperative nausea and vomiting. Also several studies reported that&#xD;
      ramosetron is effective treatment of irritable bowel syndrome because it inhibits the&#xD;
      accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and&#xD;
      the lowered colonic perceptual threshold by corticotrophin-releasing hormone. There is no&#xD;
      study about the effect of ramosetron used for preventing postoperative nausea and vomiting on&#xD;
      postoperative bowel motility. In this study, the investigators examine the effect of&#xD;
      ramosetron on postoperative bowel motility.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time from surgery to passage of gas</measure>
    <time_frame>within 10days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time from surgery to defecation</measure>
    <time_frame>within 10 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of postoperative nausea and vomiting</measure>
    <time_frame>0 - 6 hours, 6-24 hours, and 24-48 hours after surgery</time_frame>
    <description>incidence: number of patients who experienced postoperative nausea and vomiting severity: verbal rating scale (VRS, 11 point scale) 0= no nausea to 10 = worst possible nausea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received intravenous normal saline at end of surgery and 24hr after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.</description>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_label>ramosetron</arm_group_label>
    <other_name>nasea (Astellas Pharma Korea, Inc.)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20-70 yr of age,&#xD;
&#xD;
          -  ASA I or II,&#xD;
&#xD;
          -  scheduled for laparoscopic colorectal surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  antiemetic use within 24hr prior to surgery&#xD;
&#xD;
          -  steroid use within 24hr prior to surgery or 48hr after surgery&#xD;
&#xD;
          -  insulin dependent DM&#xD;
&#xD;
          -  cardiovascular or pulmonary disease&#xD;
&#xD;
          -  renal or hepatic insufficiency&#xD;
&#xD;
          -  BMI &gt;=35kg/m2&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mi Kyeong Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine, Kyung Hee University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mi Kyeong Kim, Professor</last_name>
    <phone>82-2-958-8604</phone>
    <phone_ext>92-2-958-8114</phone_ext>
    <email>mkanes@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>School of Medicine, Kyung Hee University</name>
      <address>
        <city>Seoul</city>
        <zip>130-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>August 30, 2011</last_update_submitted>
  <last_update_submitted_qc>August 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Mi Kyeong Kim</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

